Our Company

We discover and develop plant-derived cell signalling molecules to address challenging medical conditions in humans and companion animals

QBiotics has a 20 year track record in applying a scientifically-based, data-driven approach to discovery of novel, plant-derived small molecule scaffolds for applications in human and animal health using our proprietary discovery platform EcoLogic™.

Our current focus is on two unique clinical assets in oncology and wound healing

We have two high-value, inter-related programmes in oncology and wound healing which we are co-developing for both the human and companion animal markets.

Our lead oncology product, tigilanol tiglate, is a novel small molecule that is administered intratumourally and has potential to treat a broad range of solid tumours, either as a monotherapy or in combination with checkpoint inhibitor drugs (see our oncology programme).

In humans, a Phase I/IIa safety study has been completed and we are currently investigating this drug candidate's efficacy in Phase II trials in head and neck cancer, melanoma and soft tissue sarcoma.

In companion animals, tigilanol tiglate has been registered and is marketed (branded as STELFONTA®*) as a veterinary pharmaceutical for treatment of canine mast cell tumours in a number of jurisdictions and is under clinical evaluation for additional indications in dogs and horses. (*This link will take you to a product site that contains information that may not comply with the Australian regulatory requirements.)

Our lead wound healing candidate, EBC-1013, is a novel, semi-synthetic small molecule formulated as a topical gel. Preclinical models and veterinary clinical data show its potential to treat a wide range of difficult to manage wounds including chronic non-healing and traumatic acute wounds, as well as burns. This programme is currently in early clinical stage for veterinary applications and in formal preclinical development for humans. Learn more about our wound healing programme.

We have proven ability to successfully partner and to commercialise our products

The potential of our products, and the quality of the underpinning science, is recognised in our commercial partnerships with leading global pharmaceutical companies.

STELFONTA®, the veterinary formulation of our oncology drug tigilanol tiglate, has been approved for treatment of canine mast cell tumours in the USA and Europe and is being marketed and distributed under an agreement with Virbac, a global specialist animal health company.

We also have a clinical collaboration with MSD (tradename of Merck & Co. Inc, Kenilworth, NJ, USA) to evaluate the use of tigilanol tiglate as a human pharmaceutical in combination with the their immune checkpoint inhibitor drug Keytruda® (pembrolizumab) in patients with unresectable melanoma.

We have strong intellectual property protection for all our products

All our products are protected by patent families that encompass both composition of matter and use in all major jurisdictions. We also have an ongoing programme of new patent applications and patent extension activities.

A discovery pipeline underpins our potential for long-term growth

Our EcoLogic™ discovery technology provides future opportunities to expand our portfolio of therapeutic indications.

The first of these new areas, a discovery stage, next-generation antibiotic programme is ready to progress to development once our current clinical products are commercialised.


Our Story

                                             

2000

EcoBiotics established to discover novel, biologically active chemicals from Queensland's tropical rainforest
 

2000

Effectiveness of our EcoLogic™ discovery platform independently validated
 

2000

Bioactive extract libraries built for 5 major therapeutic indications
 

2003

Agreements for access to privately-owned rainforest for biodiscovery negotiated with landholders
 

2002-2004

Benefit sharing agreement signed with Queensland  Government allowing access to state-owned rainforest lands for biodiscovery
 

2004

QBiotics Limited established as a subsidiary to EcoBiotics to hold intellectual property
 

2004

Tigilanol tiglate (EBC-46) discovered as an anticancer compound
 

2005

                                             

2005

 
Shiseido discovery agreement  
 

2006

Tigilanol tiglate patent applications progress to examination phase in all major regions
 

2006

Symrise AG discovery agreement
 

2007

Tiglianol tiglate mode of action identified
 

2007

Johnson & Johnson discovery agreement
 

2008

Initial veterinary clinical case studies with tigilanol tiglate
 

2008

Tigilanol tiglate canine exploratory cases
>200 cases (89 MCT)
 

2009-2013

                                             

2010

Human and veterinary clinical development programmes for tigilanol tiglate commenced
 

2010

Tigilanol tiglate patents granted in all major markets
 

2010-2014

Dose characterisation study of tigilanol tiglate for treatment of canine mast cell tumours (MCTs) completed
 

2013

First patient treated with tigilanol tiglate in human clinical Phase I/IIa trial
 

2014

                                             

2015

IND enabling toxicology programme completed meeting requirements for both human and veterinary programmes
 

2015

US pivotal field efficacy and safety trial for tigilanol tiglate in treatment of canine MCTs completed
 

2015

QBiotics Group established following merger between EcoBiotics and QBiotics
 

2017

Agreement with Virbac for marketing & distribution of tigilanol tiglate as a veterinary pharmaceutical in EU, UK and USA
 

2018

Regulatory submission to the European Medicines Agency for tigilanol tiglate as a treatment for canine MCTs
 

2019

Tigilanol tiglate Phase I/IIa human safety trial completed
 

2019

First patient treated with tigilanol tiglate in human Phase Ib/IIa trial for head and neck squamous cell carcinoma
 

2019

Regulatory submission to US FDA Center for Veterinary Medicine for tigilanol tiglate as a treatment for canine MCTs
 

2019

Regulatory submission to Swissmedic for tigilanol tiglate as a treatment for canine MCTs
 

2019

Regulatory submission to the Australian Pesticides and Veterinary Medicines Authority for tigilanol tiglate as a treatment for canine MCTs
 

2019

                                             

2020

EMA approval and EU market launch of tigilanol tiglate for treatment of canine MCTs
 

2020

Clinical collaboration agreement with Merck Sharp & Dohme for trialling tigilanol tiglate in combination with Keytruda®
 

2020

Swissmedic approval for tigilanol tiglate as a treatment for canine MCTs
 

2020

Food and Drug Administration, Center for Veterinary Medicine (FDA-CVM) approval received for STELFONTA®
 

2020